Divalproex Sodium Tablet, Delayed Release
Product Images NDC 65862-403

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 65862-403). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Divalproex Fig1)

A bar chart comparing the percentage outcomes of placebo (PBO) versus divalproex sodium delayed-release tablets (DVPX) in two studies. Study 1 (YMRS) shows 26% for PBO and 60% for DVPX. Study 2 (MRS) shows 29% for PBO and 58% for DVPX, with significance noted at p < 0.05.*

FDA Label Image

Divalproex-fig10 (Divalproex Fig10)

Packaging label for Divalproex Sodium Delayed-Release Tablets, USP 500 mg, containing valproic acid activity. The label indicates 100 tablets in unit-dose packaging. Distributed by Aurobindo Pharma USA, Inc., made in India. NDC 65862-403-10, oral dosage form, prescription only.*

FDA Label Image

Figure 2 (Divalproex Fig2)

A line graph titled Figure 2 comparing the percent reduction in CPS rate between Divalproex Sodium delayed-release tablets and placebo. The x-axis represents the percent of patients, from 100% to 0%, and the y-axis shows percent reduction in CPS rate from -100% (worsening) to 100% (improvement), with a line for no change at 0%. The graph shows distinct curves for Divalproex Sodium and placebo, illustrating differences in patient responses.*

FDA Label Image

Figure 3 (Divalproex Fig3)

A line graph showing the % reduction in Clinical Feature Scale (CFS) rate for patients treated with Divalproex Sodium. It compares high dose versus low dose response, with percentage of patients on the x-axis and % reduction in CFS rate on the y-axis. The graph indicates levels of improvement and worsening.*

FDA Label Image

Figure 4 (Divalproex Fig4)

Bar graph titled 'Mean 4-week Migraine Rates' comparing migraine rates between placebo and Divalproex Sodium delayed-release tablets across two separate studies. The vertical axis represents migraine rates, showing lower rates for Divalproex Sodium compared to placebo in both Study 1 and Study 2. Footnotes detail dosing for each study, with doses approximately 1087 mg/day in Study 1 and 500 or 1000 mg/day in Study 2.*

FDA Label Image

Divalproex-fig5 (Divalproex Fig5)

Label for Divalproex Sodium Delayed-Release Tablets, USP, 125 mg valproic acid activity strength. The label shows it is a prescription drug with 100 tablets per bottle, manufactured by Aurobindo Pharma Limited. It includes storage instructions, distribution information by Aurobindo Pharma USA, and dosage details directing users to the full prescribing information. The label indicates the product is made in India.*

FDA Label Image

Package Label-principal Display Panel (125 mg Blister Carton (10 x 10 Unit-Dose))

Packaging label for Divalproex Sodium Delayed-Release Tablets, USP with 125 mg strength, showing valproic acid activity. The label indicates 100 tablets (10 x 10 unit-dose) and distribution by Aurobindo Pharma USA, Inc. The packaging is child-resistant and includes storage instructions. The label design features a green and blue color scheme with the Aurobindo logo.*

FDA Label Image

Divalproex-fig7 (Divalproex Fig7)

Label for Divalproex Sodium delayed-release tablets, USP, 250 mg Valproic Acid Activity strength. The label states Rx only, pharmacy dispensing instructions, storage conditions, and distributor Aurobindo Pharma USA, Inc., with manufacturing in India. The package contains 100 tablets.*

FDA Label Image

Divalproex-fig8 (Divalproex Fig8)

Packaging label for Divalproex Sodium Delayed-Release Tablets, USP 250 mg by Aurobindo Pharma Limited. The label indicates the product contains valproic acid activity equivalent to 250 mg of Divalproex sodium. The package holds 100 tablets (10 x 10 unit-dose) and includes storage instructions and dispensing guidance. Distributed by Aurobindo Pharma USA, Inc.*

FDA Label Image

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))

Label for Divalproex Sodium Delayed-Release Tablets, USP, 500 mg strength. The label states it is a prescription drug with 100 tablets per bottle. Distributed by Aurobindo Pharma USA, Inc., made in India. The label includes storage instructions, dosage form, and cautions about the bottle seal and container type. It features branding with the Aurobindo logo.*

FDA Label Image

Chemical Structure (Divalproex Str)

Chemical structure diagram depicting the polymeric form of Divalproex Sodium, showing the sodium salt of valproic acid units linked in a repeating pattern.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.